Back to top

Teleflex Closes LMA Buyout

Read MoreHide Full Article

Teleflex Incorporated (TFX - Free Report) , a global leader in medical devices used in critical care and surgery, recently closed its earlier announced acquisition of all the assets of Willemstad, Netherlands based LMA International N.V. as well as LMA’s branded laryngeal mask supraglottic airway business and other equipments of Intavent Direct Limited.

Conjointly, Teleflex expects the acquisitions to be accretive to the company’s adjusted earnings per share in the range of 3 cents to 4 cents for 2012 and 35 cents to 40 cents for 2013. This projection excludes non-recurring purchase accounting items and other costs associated with takeovers and mergers.

The acquisition will enhance Teleflex’s anesthesia product line as LMA is a global provider of medical equipment to anesthetists. LMA is also considered to be a worldwide leader in laryngeal masks which will allow Teleflex to gain market leading position for this offering.

Collectively, these acquisitions will expand Teleflex’s anesthesia and respiratory care business line. This is expected to result in a well-regarded, highly diversified business segment with annual sales of $530 million or higher. The acquisitions will also extend the company supply chain. Teleflex intends to achieve this through improved relationships with group purchasing organizations.

Limerick, Pennsylvania-based Teleflex’ focus on profitable and consistent growth is expected to yield results, helped by demographic trends and barriers to entry in the industry. The recent divestiture of its OEM Orthopedic division is expected to aid the company’s strategy of new product introduction, and investment in innovative technologies. This will accelerate the Teleflex top-line in the years ahead.

However, Covidien , C.R. Bard and CareFusion which operate in similar business segments present a tough competitive landscape for Teleflex. Additionally, the company operates in a seasoned regulatory environment. The demand for its products is susceptible to healthcare reimbursement systems in the domestic as well as the international markets.

Teleflex currently carries a Zacks #2 Rank, which translates into a short-term Buy rating.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Teleflex Incorporated (TFX) - free report >>

More from Zacks Analyst Blog

You May Like